Cargando…

New insights into the correlation between genotype and cardiac phenotype in laminopathies

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Genotype-phenotype correlation and risk stratification for heart failure progression in patients with cardiolaminopathies are poorly defined. PURPOSE: The primary aim of the present study is to characterize and correlate phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Dusi, V, Angelini, F, Elia, S, Pidello, S, Vairo, A, Callegari, M, Golzio, P G, Castagno, D, Ferraris, F, Anselmino, M, Giustetto, C, Deaglio, S, Mongini, T, Raineri, C, De Ferrari, G M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206922/
http://dx.doi.org/10.1093/europace/euad122.600
_version_ 1785046333574348800
author Dusi, V
Angelini, F
Elia, S
Pidello, S
Vairo, A
Callegari, M
Golzio, P G
Castagno, D
Ferraris, F
Anselmino, M
Giustetto, C
Deaglio, S
Mongini, T
Raineri, C
De Ferrari, G M
author_facet Dusi, V
Angelini, F
Elia, S
Pidello, S
Vairo, A
Callegari, M
Golzio, P G
Castagno, D
Ferraris, F
Anselmino, M
Giustetto, C
Deaglio, S
Mongini, T
Raineri, C
De Ferrari, G M
author_sort Dusi, V
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Genotype-phenotype correlation and risk stratification for heart failure progression in patients with cardiolaminopathies are poorly defined. PURPOSE: The primary aim of the present study is to characterize and correlate phenotype with genotype and sex. The secondary aim is to test the two main existing prognostic scores (the Arbustini and the Whabi score), both developed to predict ventricular arrhythmic events in cardiolaminopathies, for both major ventricular arrhythmias (MVA) and end-stage heart failure (ESHF). METHODS: This is a retrospective, single-center study, including patients with lamin (LMNA) and/or emerin (EMD) genetic variants. Data were collected from the first medical contact (FMC) to the last follow-up (FU). RESULTS: 28 patients (57% male, 82% probands, 68% with a family history of sudden death) were included: 96% harbored LMNA heterozygous variants, 15% had non-missense variants, 11% had variant previously never described. Functionally, 50% were variant of undetermined significance (VUS, C3), the rest were either pathogenetic or likely pathogenic (C4/C5) variants. Median age at FMC was 41 years (IQR 30-55 years), median FU was 11 years (IQR 8-18 years). At FMC, all patients had cardiac involvement, 54% had muscle involvement. By the last FU, 54% developed atrial fibrillation, 43% atrioventricular block (AVB) > I degree, 50% carried an implantable cardioverter defibrillator (21% with resynchronization), 50% had suffered at least one episode of MVA, 25% developed ESHF: 11% died due to refractory HF, 14% underwent heart transplantation (mean age 43.5 ± 9 years). The age of onset of the different types of cardiac phenotype was not influenced by sex. The penetrance of atrioventricular (AV) conduction defects (Figure 1 Panel A) and of atrial tachyarrhythmias (Figure 1 Panel B) was higher and earlier in subjects with non-missense variants. Subjects with VUS, compared to those with pathogenetic/likely pathogenetic variants, showed a significantly lower and later penetrance of MVA (Figure 2 Panel A) and a later penetrance of non- sustained ventricular tachycardia (NSVT, Figure 2, Panel B), but not of AV conduction disturbances, atrial arrhythmias, or contractile dysfunction. Arbustini score at FMC proved to be a predictor of both MVA and ESHF, while Whabi score only predicted MVA. CONCLUSIONS: In our series, the prevalence and the age of appearance of the different cardiac phenotypes of cardiolaminopathies were not influenced by sex, while the presence of VUS correlated with a lower risk of ventricular arrhythmias, but not of the other cardiac manifestations including contractile disfunction and heart failure. Our data suggest the importance of a close cardiac monitoring and of larger prospective studies even in patients with VUS. All patients developed a sever cardiac phenotype by the age of 60. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10206922
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102069222023-05-25 New insights into the correlation between genotype and cardiac phenotype in laminopathies Dusi, V Angelini, F Elia, S Pidello, S Vairo, A Callegari, M Golzio, P G Castagno, D Ferraris, F Anselmino, M Giustetto, C Deaglio, S Mongini, T Raineri, C De Ferrari, G M Europace 9.1.2 - Genetic Aspects of Arrhythmias FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Genotype-phenotype correlation and risk stratification for heart failure progression in patients with cardiolaminopathies are poorly defined. PURPOSE: The primary aim of the present study is to characterize and correlate phenotype with genotype and sex. The secondary aim is to test the two main existing prognostic scores (the Arbustini and the Whabi score), both developed to predict ventricular arrhythmic events in cardiolaminopathies, for both major ventricular arrhythmias (MVA) and end-stage heart failure (ESHF). METHODS: This is a retrospective, single-center study, including patients with lamin (LMNA) and/or emerin (EMD) genetic variants. Data were collected from the first medical contact (FMC) to the last follow-up (FU). RESULTS: 28 patients (57% male, 82% probands, 68% with a family history of sudden death) were included: 96% harbored LMNA heterozygous variants, 15% had non-missense variants, 11% had variant previously never described. Functionally, 50% were variant of undetermined significance (VUS, C3), the rest were either pathogenetic or likely pathogenic (C4/C5) variants. Median age at FMC was 41 years (IQR 30-55 years), median FU was 11 years (IQR 8-18 years). At FMC, all patients had cardiac involvement, 54% had muscle involvement. By the last FU, 54% developed atrial fibrillation, 43% atrioventricular block (AVB) > I degree, 50% carried an implantable cardioverter defibrillator (21% with resynchronization), 50% had suffered at least one episode of MVA, 25% developed ESHF: 11% died due to refractory HF, 14% underwent heart transplantation (mean age 43.5 ± 9 years). The age of onset of the different types of cardiac phenotype was not influenced by sex. The penetrance of atrioventricular (AV) conduction defects (Figure 1 Panel A) and of atrial tachyarrhythmias (Figure 1 Panel B) was higher and earlier in subjects with non-missense variants. Subjects with VUS, compared to those with pathogenetic/likely pathogenetic variants, showed a significantly lower and later penetrance of MVA (Figure 2 Panel A) and a later penetrance of non- sustained ventricular tachycardia (NSVT, Figure 2, Panel B), but not of AV conduction disturbances, atrial arrhythmias, or contractile dysfunction. Arbustini score at FMC proved to be a predictor of both MVA and ESHF, while Whabi score only predicted MVA. CONCLUSIONS: In our series, the prevalence and the age of appearance of the different cardiac phenotypes of cardiolaminopathies were not influenced by sex, while the presence of VUS correlated with a lower risk of ventricular arrhythmias, but not of the other cardiac manifestations including contractile disfunction and heart failure. Our data suggest the importance of a close cardiac monitoring and of larger prospective studies even in patients with VUS. All patients developed a sever cardiac phenotype by the age of 60. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10206922/ http://dx.doi.org/10.1093/europace/euad122.600 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 9.1.2 - Genetic Aspects of Arrhythmias
Dusi, V
Angelini, F
Elia, S
Pidello, S
Vairo, A
Callegari, M
Golzio, P G
Castagno, D
Ferraris, F
Anselmino, M
Giustetto, C
Deaglio, S
Mongini, T
Raineri, C
De Ferrari, G M
New insights into the correlation between genotype and cardiac phenotype in laminopathies
title New insights into the correlation between genotype and cardiac phenotype in laminopathies
title_full New insights into the correlation between genotype and cardiac phenotype in laminopathies
title_fullStr New insights into the correlation between genotype and cardiac phenotype in laminopathies
title_full_unstemmed New insights into the correlation between genotype and cardiac phenotype in laminopathies
title_short New insights into the correlation between genotype and cardiac phenotype in laminopathies
title_sort new insights into the correlation between genotype and cardiac phenotype in laminopathies
topic 9.1.2 - Genetic Aspects of Arrhythmias
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206922/
http://dx.doi.org/10.1093/europace/euad122.600
work_keys_str_mv AT dusiv newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT angelinif newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT elias newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT pidellos newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT vairoa newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT callegarim newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT golziopg newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT castagnod newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT ferrarisf newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT anselminom newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT giustettoc newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT deaglios newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT monginit newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT raineric newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies
AT deferrarigm newinsightsintothecorrelationbetweengenotypeandcardiacphenotypeinlaminopathies